Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

LA JOLLA, Calif., Nov. 14 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced financial results for the third quarter ended September 30, 2007. For the three-month period, the Company posted revenue of $2.5 million and a net loss of $6.8 million. Cash and cash equivalents totaled $39.7 million at September 30, 2007.

"Last quarter we continued to advance our three priority product candidates and most notably, after the quarter ended, we announced positive results from our Phase IIb clinical trial evaluating our lead compound, tezampanel, in acute migraine," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "We now have two migraine studies in which tezampanel demonstrated statistically significant improvement on the primary end point of pain response at two hours post-dose compared to placebo. These Phase IIb results further establish the efficacy and safety of tezampanel and we are pleased to be advancing tezampanel into later-stage clinical development."

Highlights:

-- In October 2007, announced that tezampanel met the primary endpoint at

the 40 mg dose in a 306-patient, Phase IIb clinical trial for the

treatment of a single, acute migraine attack. Two other doses, 70 mg

and 100 mg, were evaluated and also demonstrated effects across a

number of pain measurements although neither dose reached statistical

significance on the primary endpoint. In this trial, tezampanel was

well-tolerated and there were no serious or medically important

adverse events reported.

-- Initiated a Phase I multiple-dose clinical trial of tezampanel to

evaluate the safety, tolerability
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... German . , ... demonstrated a new kind of building block for digital ... could be based on three-dimensional arrangements of nanometer-scale magnets ... the semiconductor industry CMOS fabrication of silicon chips ... at the University of Notre Dame are exploring "magnetic ...
(Date:9/30/2014)... 30, 2014 Report Details Biosimilar ... potential revenues Do you want to find sales ... revenue predictions for those biological drugs from 2014, ... find financial data, R&D trends, opportunities and selling ... forecasts to 2024 at overall world market, therapeutic ...
(Date:9/30/2014)... 2014 Over the last decade, the ... rising R&D budgets and increased acceptance of new filtration ... and biotechnology industries are also catalyzing the growth of ... is expected to grow at a strong CAGR during ... be worth $2,532.6 million by 2019. The market is ...
(Date:9/30/2014)... Md. , Sept. 30, 2014  RegeneRx ... today announced that it has received a Canadian ... by Actin-Sequestering Peptides.  This patent includes claims using ... numerous other actin-sequestering peptides for these purposes.  The ... About RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
Breaking Biology Technology:A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... Olive Branch Fund: A Thisbe and Noah Scott Legacy, ... today announced its first funding award to Kevin Eggan, ... at Harvard University.  The award will support Dr. Eggan,s ... that affect it.  Dr. Eggan is a leading researcher ...
... PRINCETON, N.J., June 29, 2011 PharmaNet Development Group, Inc. ... its cash tender offer and consent solicitation (the "Offer") for ... Notes due 2017 (the "Notes"), it has elected to extend ... York City time, on July 6, 2011, unless extended or ...
... Associates® - San Francisco, a specialized executive search firm ... arena, welcomes Eduard Alberts, Ph.D. as Vice President and ... of experience and success in the life sciences industry, ... companies and a wide array of cultures. His prior ...
Cached Biology Technology:The Olive Branch Fund Announces Funding Award to Harvard Researcher 2PharmaNet Extends Expiration Time in its Tender Offer and Consent Solicitation 2PharmaNet Extends Expiration Time in its Tender Offer and Consent Solicitation 3Eduard Alberts, Ph.D. Joins Sanford Rose Associates - San Francisco 2
(Date:9/30/2014)... on Earth, but when the climate changes and temperatures ... The amount of time needed to adjust to new ... in the future, reveals a new study from researchers ... journal Proceedings of the Royal Society B . ... of greenhouse gases in the atmosphere. The greenhouse effect ...
(Date:9/30/2014)... you want your doctor to know what goes wrong with ... good idea to know what "normal" actually is. That,s where ... of the FASEB Journal comes in. ... transcriptomea key set of molecules that can help scientists "see" ... time. What,s more, they found never-before-detected gene activity and that ...
(Date:9/30/2014)... 2014) People who suffer from asthma may think ... their asthma besides properly taking medications and avoiding allergic ... the Annals of Allergy, Asthma and Immunology , ... Asthma and Immunology (ACAAI), asthma sufferers can learn lessons ... woman described in the Annals article improved her asthma ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Scientists identify which genes are active in muscles of men and women 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... penguins in Antarctica than was previously thought, according to ... of researchers using high-resolution satellite mapping technology. This first-ever ... important benchmark for monitoring the impact of environmental change ... from the University of Minnesota Polar Geospatial Center co-authored ...
... press release is available in German . , ... beings in their own right. This changed about one billion years ... cells. Since then, they have lost much of their autonomy. As ... into the cell nucleus; today, chloroplasts would no longer be able ...
... Calif.All animals seem to have ways of exchanging informationmonkeys ... and fireflies light up their bellies to attract mates. ... among the most abundant animals on the planet, little ... led by California Institute of Technology (Caltech) biologists has ...
Cached Biology News:Scientists complete first-ever emperor penguin count from space 2Direct transfer of plant genes from chloroplasts into the cell nucleus 2Decoding worm lingo 2Decoding worm lingo 3
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
Carrier-Free Recombinant Human Flt-3/Flk-2 Ligand (Flt3/Flk2 Ligand, Flt3L, Flt3-L, Flk2L, Flk2-L) 100 ug...
Anti-CD74 Monoclonal Antibody Description: 200 l Research Focus: cell surface antigens Storage: 4C Shipping Temperature: 4C...
POU domain, class 2, transcription factor 2,...
Biology Products: